Portal de Periódicos da CAPES

DOUBLE-BLIND MULTICENTER STUDY COMPARING ALPROSTADIL α-CYCLODEXTRIN WITH MOXISYLYTE CHLORHYDRATE IN PATIENTS WITH CHRONIC ERECTILE DYSFUNCTION

1998; Lippincott Williams & Wilkins; Volume: 159; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(01)64030-8

1527-3792

Irène Buvat, P. Costa, D Morlier, Brigitte Lecocq, Barbara J. Stegmann, Detlef Albrecht,

Sexuality, Behavior, and Technology

No AccessJournal of UrologyClinical Urology: Original Articles1 Jan 1998DOUBLE-BLIND MULTICENTER STUDY COMPARING ALPROSTADIL α-CYCLODEXTRIN WITH MOXISYLYTE CHLORHYDRATE IN PATIENTS WITH CHRONIC ERECTILE DYSFUNCTION Jacques Buvat, Pierre Costa, Dominique Morlier, Brigitte Lecocq, Barbara Stegmann, and Detlef Albrecht Jacques BuvatJacques Buvat , Pierre CostaPierre Costa , Dominique MorlierDominique Morlier , Brigitte LecocqBrigitte Lecocq , Barbara StegmannBarbara Stegmann , and Detlef AlbrechtDetlef Albrecht View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)64030-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compared the efficacy and safety of alprostadil alpha-cyclodextrin and moxisylyte chlorhydrate to induce erections adequate for sexual intercourse in a prospective, randomized, parallel double-blind study in patients with erectile dysfunction. Materials and Methods: A total of 156 men with erectile dysfunction due to organic, nonorganic and mixed origin was randomized into 2 parallel treatment groups receiving titrations of an individual optimum dose of alprostadil alpha-cyclodextrin or moxisylyte chlorhydrate. Erectile response was measured by the buckling test. A positive test was associated with axial erection rigidity that did not buckle/deform to 1.0 kg. load. The buckling test was repeated every 10 minutes for up to 60 minutes. Results: A total of 56 patients (75%) in the alprostadil alpha-cyclodextrin group and 32 patients (40%) in the moxisylyte chlorhydrate group responded with at least 1 positive buckling test during the office period. Investigators assessed erections after alprostadil alpha-cyclodextrin to be adequate for sexual intercourse in 61 patients (81%) compared to 37 patients (46%) after moxisylyte chlorhydrate. All efficacy parameters in office reached statistical significance of p <0.001 in favor of alprostadil alpha-cyclodextrin. During self-injection therapy at home 58 patients (85%) reported at least 1 rigid erection after alprostadil alpha-cyclodextrin compared to 37 patients (61%) after moxisylyte chlorhydrate. Patient and partner opinion of treatment statistically significantly better scores in the alprostadil alpha-cyclodextrin group compared to the moxisylyte chlorhydrate group. Conclusions: Alprostadil alpha-cyclodextrin is significantly more effective than moxisylyte chlorhydrate in producing full penile rigidity in office and at home. Injection related side effects occur with the same frequency but moxisylyte results in more systemic side effects and alprostadil results in more painful and prolonged erections. Patients and partners are significantly more satisfied with alprostadil alpha-cyclodextrin. References 1 : Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence.. Brit. J. Psychiat.1983; 143: 332. Google Scholar 2 : Intracavernous injection of papaverine for erectile failure.. Lancet1982; 11: 938. Google Scholar 3 : Pharmacotherapy of erectile dysfunction: a review.. Int. J. Impotence Res.1989; 1: 71. Google Scholar 4 : Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo.. J. Urol.1993; 149: 301. Abstract, Google Scholar 5 : Studies on male sexual impotence, report 18. Therapeutic trial with Prostaglandin E1 for organic impotence.. Nippon Hinyokika Gakkai Zasshi1986; 77: 954. Google Scholar 6 : Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction.. V.A.S.A., suppl.1989; 28: 50. Google Scholar 7 : Safety of intracavernous injections using an alpha-blocking agent.. J. Urol.1989; 141: 1364. Abstract, Google Scholar 8 : Reduced rate of fibrotic nodules in the cavernous bodies following auto-intracavernous injection of moxisylyte compared to papaverine.. Int. J. Impotence Res.1991; 3: 123. Google Scholar 9 : Intracavernous pharmacotherapy: comparison of moxisylyte and prostaglandin E1.. Int. J. Impotence Res.1996; 8: 41. Google Scholar 10 : The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.. J. Urol.1996; 155: 802. Abstract, Google Scholar 11 : Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction.. New Engl. J. Med.1996; 334: 873. Google Scholar 12 : Measurement of pressure necessary for vaginal penetration.. Sleep Res.1985; 14: 269A. Google Scholar 13 : Comparison of RigiScan and formal nocturnal penile tumescence testing in the evaluation of erectile rigidity.. J. Urol.1993; 149: 1265. Abstract, Google Scholar 14 : Comparison of RigiScan and sleep laboratory nocturnal penile tumescence in the diagnosis of organic impotence.. J. Urol.1995; 154: 1740. Abstract, Google Scholar 15 : Efficacite et tolerance du moxisylyte en injection intracaverneuse chez le patient presentant un dysfonctionnement erectile: relation effect/dose versus placebo.. Progress en Urologie1995; 5: 690. Google Scholar 16 : Is the volume injected a parameter likely to influence the erectile response observed after intracavernous administration of an alpha-blocking agent?. Eur. Urol.1993; 24: 43. Google Scholar 17 : Intracavernous alprostadil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.. Drug & Aging.1996; 8: 56. Google Scholar From the Association EPARP, Lille, Departments of Urology, Hopital G. Doumergue, Nimes and Hopital Tenon, Paris, Laboratoires Schwarz Pharma, France and Schwarz Pharma A.G., Monheim, GermanyAccepted for publication July 25, 1997Supported by Schwarz Pharma A.G., Mannheim, GermanyDetlef Albrecht for the Study Group; Participating investigators: E. Amar, L. Boccon-Gibbod, D. Morlier and G. Arvis, Paris; J. Buvat and A. Lemaire, Lille; O. Cambau and A. Leriche, Saint Genis Laval; D. Chevalier, Nice; P. Costa and H. Navratil, Nimes; P. Desvaux, Clichy; J. Hermabessiere, Clermont-Ferrand; F. Giuliano, A. Jardin, Le Kremlin Bicetre, P. Lansiaux and B. Dufour, Paris; M. Schouman, Neuilly, and A. Gout, H. Zerbib and R. Debre, Paris, France© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySASSO F, GULINO G, WEIR J, VIGGIANO A and ALCINI E (2018) PATIENT SELECTION CRITERIA IN THE SURGICAL TREATMENT OF VENO-OCCLUSIVE DYSFUNCTIONJournal of Urology, VOL. 161, NO. 4, (1145-1147), Online publication date: 1-Apr-1999. Volume 159Issue 1January 1998Page: 116-119 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information Jacques Buvat More articles by this author Pierre Costa More articles by this author Dominique Morlier More articles by this author Brigitte Lecocq More articles by this author Barbara Stegmann More articles by this author Detlef Albrecht More articles by this author Expand All Advertisement PDF downloadLoading ...